David Abrams
Abrams Capital Management
David Abrams Keryx Biopharmaceuticals Inc stake
total: 84
Abrams Capital Management KERX trades
- Total transactions:
- 7
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 1
- Held since:
- 2015 Q3
- Held for:
- 13 quarters
- Latest activity:
- 2018 Q4
According to 2026 Q2 report, David Abrams doesn't hold any Keryx Biopharmaceuticals Inc (KERX) shares. To date, the estimated cost basis is nearly $4.08 for "buy" trades and estimated average "sell" price is $3.4. Abrams Capital Management first purchased KERX in 2015 Q3, initially acquiring about 5.00M shares. Since the initial investment in Keryx Biopharmaceuticals Inc (KERX), Abrams Capital Management has made 6 more transactions.
When did David Abrams sell Keryx Biopharmaceuticals Inc (KERX)?
David Abrams sold off the entire Keryx Biopharmaceuticals Inc (KERX) position in 2018 Q4.
When did David Abrams buy Keryx Biopharmaceuticals Inc (KERX)?
David Abrams first invested in Keryx Biopharmaceuticals Inc (KERX) in 2015 Q3 at the reported quarter-end price of $3.52 per share.
What's the cost basis of Abrams Capital Management's KERX stake?
The estimated cost basis for Keryx Biopharmaceuticals Inc (KERX) stake is around $4.08 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $4.08
- Weighted AVG sell price:
- $3.40
David Abrams's historical trades in Keryx Biopharmaceuticals Inc
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2018 Q4
|
0.00%
|
$3.40
|
-100% (-9,108,867)
|
|||
|
2018 Q3
|
0.82%
|
$3.40
|
-8.45% (-841,188)
|
|||
|
2018 Q2
|
1.04%
|
$3.76
|
+2.38% (+230,879)
|
|||
|
2017 Q4
|
1.52%
|
$4.65
|
+69.94% (+4,000,000)
|
|||
|
2016 Q1
|
1.26%
|
$4.67
|
+3.99% (+219,176)
|
|||
|
2015 Q4
|
1.52%
|
$5.05
|
+10.00% (+500,000)
|
|||
|
2015 Q3
|
1.26%
|
$3.52
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.